Sino Biopharmaceutical (HKSE:01177) Sale Of Investment : HK$2,802 Mil (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Sale Of Investment?

Sino Biopharmaceutical's sale of investment for the six months ended in Dec. 2023 was HK$1,978 Mil. It means Sino Biopharmaceutical gained HK$1,978 Mil from selling investments. Sino Biopharmaceutical's sale of investment for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,802 Mil.

Compared with last quarter (HK$823 Mil in Jun. 2023 ), Sino Biopharmaceutical gained more money from selling investments in Dec. 2023 (HK$1,978 Mil).

Sino Biopharmaceutical Sale Of Investment Historical Data

The historical data trend for Sino Biopharmaceutical's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Sale Of Investment Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sale Of Investment

Get a 7-Day Free Trial

1,017.35

6,070.91

1,105.99

1,204.96

2,801.68

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Sale Of Investment	Get a 7-Day Free Trial															-1,912.29	667.57	568.99	823.49	1,978.19

Sino Biopharmaceutical Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2,802 Mil.

Sino Biopharmaceutical Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Executives

Tse Eric S Y	2101 Beneficial owner
Tse Ping	2101 Beneficial owner
Cheng Cheung Ling	2101 Beneficial owner
True Merit Global Limited	2101 Beneficial owner
Tse Theresa Y Y	2101 Beneficial owner
Thousand Eagles Limited	2101 Beneficial owner
France Investment (china 1) Group Limited	2101 Beneficial owner
Remarkable Industries Limited	2101 Beneficial owner
Validated Profits Limited	2101 Beneficial owner

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines